Salt Lake-based biopharmaceutical company Myriad Genetics Inc. on Tuesday said that the underwriters have exercised in full their over-allotment option to purchase more than 1 million additional shares of common stock at a public offering price of $18.50 per share.

The closing of the purchase of the over-allotment shares will take place simultaneously today with the closing of the initial sale of 7 million shares.

Myriad said it is expecting the sale of more than 8 million shares to result in gross proceeds, before commissions and expenses, of about $148.9 million.